Skip to Content

Modified-FOLFIRINOX Beneficial in Resected Pancreatic Cancer

WEDNESDAY, Dec. 19, 2018 -- For patients with resected pancreatic cancer, adjuvant therapy with a modified regimen of chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX), compared with gemcitabine, results in significantly longer survival, according to a study published in the Dec. 20 issue of the New England Journal of Medicine.

Thierry Conroy, M.D., from the Institut de Cancérologie de Lorraine in Vandoeuvre-lès-Nancy, France, and colleagues randomly assigned 493 patients with resected pancreatic ductal adenocarcinoma to receive either a modified FOLFIRINOX regimen or gemcitabine for 24 weeks.

The researchers found median disease-free survival rates of 21.6 and 12.8 months in the modified-FOLFIRINOX and gemcitabine groups, respectively, during a median follow-up of 33.6 months (stratified hazard ratio for cancer-related event, second cancer, or death, 0.58). At three years, disease-free survival rates were 39.7 and 21.4 percent in the modified-FOLFIRINOX and gemcitabine groups, respectively. Median overall survival was 54.4 and 35.0 months, respectively, in the modified-FOLFIRINOX and gemcitabine groups (stratified hazard ratio for death, 0.64). At three years, overall survival rates were 63.4 and 48.6 percent in the modified-FOLFIRINOX and gemcitabine groups, respectively. Grade 3 or 4 adverse events occurred in 75.9 and 52.9 percent of patients in the modified-FOLFIRINOX and gemcitabine groups, respectively.

"This trial represents the culmination of more than a decade of careful work that initially established FOLFIRINOX as a standard treatment for advanced pancreatic cancer," write the authors of an accompanying editorial.

Several authors disclosed financial ties to the pharmaceutical industry; the study was partially funded by R&D Unicancer, which received a grant from Chugai Pharmaceutical.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

© 2020 HealthDay. All rights reserved.

Posted: December 2018

Read this next

UEG: Pancreatic CA Down With Bariatric Sx for Obese With DM

FRIDAY, Oct. 16, 2020 -- For patients with diabetes mellitus and obesity, bariatric surgery (BS) is associated with a reduced prevalence of pancreatic cancer compared with no BS,...

Recent Diabetes + Weight Loss Tied to Pancreatic Cancer Risk

TUESDAY, Aug. 18, 2020 -- Recent-onset diabetes accompanied by weight loss is associated with a substantially increased risk for developing pancreatic cancer, according to a study...

Platinum Therapy May Up Survival in Pancreatic Cancer With DNA Repair Defects

TUESDAY, May 26, 2020 -- For patients with advanced-stage pancreatic ductal adenocarcinoma (PDAC), those with homologous recombination deficiency (HRD) have improved survival with...